Owkin
PrivateLast Round
Series B
Extension
Jun 8, 2022
Est. Valuation
$1.46B
Total Funding Raised
$356.1M
Company Overview
Owkin is a biotechnology and healthcare technology company that develops agentic AI and machine learning solutions to accelerate drug discovery, clinical development, and diagnostics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Owkin Comparables
Compare Owkin with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BenchSci | 84% | |
| Insilico Medicine | 83% | |
| Partex | 82% |
Owkin Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jun 8, 2022 | ||||
| Series B | Nov 18, 2021 | ||||
| Series A | Jun 30, 2020 | ||||
| Series A Extension | May 7, 2020 | ||||
| Series A Extension | Mar 7, 2019 | ||||
Series A Extension | May 23, 2018 |
Key People
Founding team and executive leadership
Owkin Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GV | Series A, Series A Extension |
| Plug and Play Tech Center | Series A |
| NJF Capital | Series A, Series A Extension, Seed |
| Otium Capital | Series A |
| F-Prime Capital | Series A, Series A Extension |
| Eight Roads Ventures | Series A, Series A Extension |
| Otium Capital Ltd. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 2, 2026
Introduced Owkin Zero, an LLM fine-tuned on biology.
- Mar 3, 2026
Partnered with Consensus to integrate scientific literature intelligence.
Recent news
Latest coverage and updates
- partners_withSep 29, 2026
Owkin partnered with Metrosert on Sep 29th '26.
- partners_withSep 2, 2026
Owkin partnered with Boehringer Ingelheim Pharmaceuticals, Inc. on Sep 2nd '26.
Owkin Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Owkin's valuation, stock price, and market status.
Is Owkin a public or private company?
Owkin is a private company.
What is the current stock price of Owkin?
Owkin is a private company, so its shares have no public market price. Caplight tracks Owkin's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Owkin worth (valuation)?
Owkin's valuation is estimated at $1.5B based on funding round data.
Can I buy Owkin stock?
Owkin shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Owkin's last funding round?
Owkin's most recent funding round was Series B Extension on June 8, 2022.
Who are the main investors in Owkin?
Key investors in Owkin include GV, Otium Capital, F-Prime Capital, Eight Roads Ventures, Otium Capital Ltd..
Will Owkin IPO soon?
No public IPO plans have been announced for Owkin.
How can I track Owkin secondary market activity?
Caplight tracks bids, offers, and trades in Owkin's shares on secondary markets.